[go: up one dir, main page]

DE60118889D1 - Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs - Google Patents

Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs

Info

Publication number
DE60118889D1
DE60118889D1 DE60118889T DE60118889T DE60118889D1 DE 60118889 D1 DE60118889 D1 DE 60118889D1 DE 60118889 T DE60118889 T DE 60118889T DE 60118889 T DE60118889 T DE 60118889T DE 60118889 D1 DE60118889 D1 DE 60118889D1
Authority
DE
Germany
Prior art keywords
breast cancer
protein transferase
treatment
transferase inhibitors
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118889T
Other languages
English (en)
Other versions
DE60118889T2 (de
Inventor
Peter Albert Palmer
David Horak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE60118889D1 publication Critical patent/DE60118889D1/de
Application granted granted Critical
Publication of DE60118889T2 publication Critical patent/DE60118889T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60118889T 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs Expired - Lifetime DE60118889T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200373 2000-02-04
EP00200373 2000-02-04
PCT/EP2001/001032 WO2001056552A2 (en) 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitors for treating breast cancer

Publications (2)

Publication Number Publication Date
DE60118889D1 true DE60118889D1 (de) 2006-05-24
DE60118889T2 DE60118889T2 (de) 2006-11-30

Family

ID=8170976

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118889T Expired - Lifetime DE60118889T2 (de) 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs

Country Status (13)

Country Link
US (4) US20030027839A1 (de)
EP (1) EP1255537B1 (de)
JP (1) JP5491681B2 (de)
AT (1) ATE323474T1 (de)
AU (1) AU2001233726A1 (de)
CA (1) CA2396865C (de)
CY (1) CY1105477T1 (de)
DE (1) DE60118889T2 (de)
DK (1) DK1255537T3 (de)
ES (1) ES2262626T3 (de)
PT (1) PT1255537E (de)
SI (1) SI1255537T1 (de)
WO (1) WO2001056552A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
NZ532562A (en) * 2001-11-30 2007-02-23 Schering Corp Use of an FPT inhibitor in combination with other antineoplastic agents for the manufacture of a medicament to be used in the treatment of cancer
US7102251B2 (en) * 2003-08-22 2006-09-05 Distributed Power, Inc. Bi-directional multi-port inverter with high frequency link transformer
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
EP1692111A2 (de) 2003-12-12 2006-08-23 Wyeth, A Corporation of the State of Delaware Zur behandlung von herzkreislaufkrankheiten geeignete chinoline
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
EP1744751A4 (de) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
EP1732549A4 (de) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP2009521470A (ja) 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2288195B1 (de) * 2009-08-20 2019-10-23 Samsung Electronics Co., Ltd. Verfahren und Vorrichtung zum Betreiben einer Basisstation in einem drahtlosen Kommunikationssystem
ME02794B (de) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Methylengebundene chinolinylmodulatoren von ror-gamma-t
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
PT3385395T (pt) 2015-08-17 2020-05-06 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
US11124839B2 (en) 2016-11-03 2021-09-21 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711142B2 (en) * 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
WO2000001701A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP4530537B2 (ja) * 1998-07-06 2010-08-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
IL143859A0 (en) * 1998-12-23 2002-04-21 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1267848B1 (de) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
JP2003525255A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
US20020022633A1 (en) * 2000-06-30 2002-02-21 Williams Theresa M. Inhibitors of prenyl-protein transferase

Also Published As

Publication number Publication date
JP2003521509A (ja) 2003-07-15
EP1255537A2 (de) 2002-11-13
CA2396865A1 (en) 2001-08-09
ATE323474T1 (de) 2006-05-15
US20110098318A1 (en) 2011-04-28
WO2001056552A3 (en) 2002-04-25
ES2262626T3 (es) 2006-12-01
US20090018164A1 (en) 2009-01-15
US20040192726A1 (en) 2004-09-30
JP5491681B2 (ja) 2014-05-14
SI1255537T1 (sl) 2006-10-31
US20030027839A1 (en) 2003-02-06
EP1255537B1 (de) 2006-04-19
CY1105477T1 (el) 2010-04-28
AU2001233726A1 (en) 2001-08-14
DE60118889T2 (de) 2006-11-30
DK1255537T3 (da) 2006-08-21
CA2396865C (en) 2009-04-14
WO2001056552A2 (en) 2001-08-09
PT1255537E (pt) 2006-09-29

Similar Documents

Publication Publication Date Title
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
DE60130976D1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE323490T1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60020269D1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
DE602004017481D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
ATE438618T1 (de) Inhibitoren von humanem adam-10
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE386029T1 (de) Urokinase-inhibitoren
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
8364 No opposition during term of opposition